The first non-stimulant ADHD drug approved by the FDA was Strattera (atomoxetine), which was approved in 2002. It marked a significant milestone in ADHD treatment, offering an alternative to stimulant medications like methylphenidate and amphetamines.
FDA Approval History
Before Strattera, the only approved treatments for ADHD were stimulants. While effective, stimulants carried a risk of misuse and side effects such as insomnia and appetite loss. Strattera, developed by Eli Lilly, was the first non-stimulant medication to be recognized for its ability to manage ADHD symptoms without these issues. It was approved after extensive clinical trials demonstrated its safety and effectiveness.
Mechanism of Action
Unlike stimulants, which work by increasing dopamine levels in the brain, Strattera works by selectively inhibiting the reuptake of norepinephrine. By boosting norepinephrine activity, it helps improve focus, attention, and impulse control. This mechanism makes Strattera a suitable option for individuals who cannot tolerate stimulants or have a history of substance abuse, as it does not carry the same risk of misuse.
Strattera Benefits and Side Effects
Strattera is often preferred for individuals who need a non-stimulant medication due to its lower abuse potential. While it can take several weeks to show full effectiveness, many patients benefit from its steady symptom relief. Common side effects include fatigue, decreased appetite, and stomach upset, but these are generally milder than stimulant-related side effects.
In conclusion, Strattera was the first non-stimulant ADHD drug to be approved, providing a safer alternative for long-term treatment and expanding ADHD treatment options.
Visit providers like ADHD Certify for personal consultations and expert guidance tailored to your unique situation.
For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medications for ADHD.
